Single-cell transcriptomics identifies ergothioneine as a mitochondrial protector to prevent AKI-to-CKD progression
PLOS One · 2026
DOI: 10.1371/journal.pone.0351630 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Jiaxin Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Mitochondria, Ergothioneine, Transcriptome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital, Hubei Provincial Natural Science Foundation.
Abstract (Originalsprache)
This study investigates the role and mechanism of ergothioneine (EGT) in mitigating the progression of acute kidney injury (AKI) to chronic kidney disease (CKD). Using a cisplatin-induced mouse model of the AKI-to-CKD transition with EGT intervention, we combined histopathological examination, biochemical assays, and single-cell RNA sequencing (scRNA-seq) to provide evidence that EGT may improve renal function parameters and attenuate renal injury and fibrosis. scRNA-seq analysis revealed that EGT was associated with partial normalization of mitochondria-related gene expression in renal tubular epithelial cells, accompanied by enrichment of oxidative phosphorylation and electron transport chain pathways. Furthermore, our in vitro experiments supported a protective association of EGT with mitochondrial injury-related phenotypes in injured renal tubular epithelial cells, as indicated by reduced reactive oxygen species generation, partial preservation of mitochondrial membrane potential, and increased cellular ATP levels. These findings suggest that EGT may attenuate AKI-to-CKD progression in association with improved mitochondrial homeostasis, offering a potential therapeutic strategy for kidney diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei, China.
ORCID-Profile: Ling Chen
Förderung
- National Key R&D Program of China
- Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital
- Hubei Provincial Natural Science Foundation
Zitieren
APA
Peng, J., Chen, J., Qian, Z., Han, M., & Chen, L. (2026). Single-cell transcriptomics identifies ergothioneine as a mitochondrial protector to prevent AKI-to-CKD progression. PLOS One. https://doi.org/10.1371/journal.pone.0351630
Vancouver
Peng J, Chen J, Qian Z, Han M, Chen L. Single-cell transcriptomics identifies ergothioneine as a mitochondrial protector to prevent AKI-to-CKD progression. PLOS One. 2026. doi:10.1371/journal.pone.0351630
BibTeX
@article{Peng2026,
author = {Peng, Jiaxin and Chen, Jing and Qian, Zhipu and Han, Mingzhang and Chen, Ling},
title = {Single-cell transcriptomics identifies ergothioneine as a mitochondrial protector to prevent AKI-to-CKD progression},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0351630}
}
EUVIMED